-
Infinity Pharmaceuticals Inc. (NASDAQ: INFI)
shares dipped 70.63 percent to $1.29. Infinity announced plans to cut 21 percent of the workforce. The company also reported
that DYNAMO Phase 2 monotherapy study evaluating the efficacy and safety of duvelisib met its primary endpoint.
-
Mesoblast limited (ADR) (NASDAQ: MESO) shares
fell 36.03 percent to $4.52 as the company issued an update on global heart failure program. The company reported that it has
regained rights to cardiovascular field for cell therapy platform.
-
KemPharm Inc (NASDAQ: KMPH) shares fell 26.23
percent to touch a new 52-week low of $4.64 after the company reported that it has received a Complete Response Letter from the
FDA regarding its Apadaz NDA .
-
Dataram Corp (NASDAQ: DRAM) dropped 25.69 percent
to $1.07 as the company reached a deal to acquire all of the outstanding shares of US Gold Corp and USGC subsidiaries.
-
Revance Therapeutics Inc (NASDAQ: RVNC) shares
fell 23.02 percent to $14.12 as the company reported that its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel
(RT001) to treat patients with moderate to severe lateral canthal lines (crow’s feet) had failed to meet co-primary and other
endpoints.
-
ImmunoGen, Inc. (NASDAQ: IMGN) shares fell 16.87
percent to $4.11 after the company announced a private offering of $100 million in convertible senior notes.
-
Innocoll Holdings PLC (NASDAQ: INNL) dropped
13.82 percent to $9.48 as the company reported a proposed public offering of $65 million.
-
Navistar International Corp (NYSE: NAV) shares
declined 13.69 percent to $11.35. Stifel Nicolaus downgraded Navistar from Hold to Sell.
-
Western Gas Equity Partners LP (NYSE: WGP) shares
fell 9.25 percent to $37.88. Western Gas Equity Partners priced 12.5 million common unit offering for gross proceeds of $481
million.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.